Table 2.

Clinical guidelines for osteoporosis therapy

OrganizationRecommendations for treatmentOsteoporosis therapy indicated in these 6 cases
American Society of Clinical Oncology (2010; ref. 55)*Postmenopausal women with hormone receptor-positive breast cancer should consider incorporating AI therapy during adjuvant treatment.No
AI therapy should not exceed 5 years, though the optimal timing and duration of endocrine treatment is unresolved.
National Osteoporosis Foundation (2001; ref. 94)2003: Treatment thresholdYes
(a) T-score −2.0 without risk factors;
(b) T-score −1.5 with risk factors.
World Health Organization (2008; ref. 95)Treatment threshold:Yes (in the case of osteoporosis, not in osteopenia)
20% risk of any fracture in 10 years or 3% risk of hip fracture in 10 years
Patients present
10 year risk of fracture 4.8%
10 year risk of hip fracture 0.3%
International Society of Clinical Densitometry (2006)BMD assessment in patients at risk for bone loss because of age (women aged ≥ 65 years and men aged ≥ 70 years), postmenopausal status with other risk factors, prior fragility fracture, medication use or disease or medical conditionDoes not define treatment threshold
American College of Rheumatology (2001) Prevention and Treatment of Glucocorticoid induced osteoporosisOsteoporosis therapy is indicated in individuals who have a T-score ≤ −1.0Yes
  • *Clinical guidelines for CTIBL.

  • †Postmenopausal osteoporosis.

  • ‡Glucocorticoid induced osteoporosis.